MANKIND PHARMA Financial Statement Analysis
|
||
|
The Revenues of MANKIND PHARMA have increased by 12.44% YoY .
The Earnings Per Share (EPS) of MANKIND PHARMA has increased by 49.22 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
MANKIND PHARMA Last 5 Annual Financial Results
[BOM: 543904|NSE : MANKIND]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹8,749 Cr | ₹7,782 Cr | ₹621 Cr | ₹58,719 Cr | ₹4,980 Cr |
| Expenses | ₹6,848 Cr | ₹5,791 Cr | ₹457 Cr | ₹44,272 Cr | ₹4,055 Cr |
| Operating Profit (Excl OI) | ₹1,902 Cr | ₹1,991 Cr | ₹165 Cr | ₹14,447 Cr | ₹925 Cr |
| Other Income | ₹129 Cr | ₹196 Cr | ₹17 Cr | ₹1,038 Cr | ₹53 Cr |
| Interest | ₹46 Cr | ₹60 Cr | ₹2.12 Cr | ₹232 Cr | ₹44 Cr |
| Depreciation | ₹326 Cr | ₹167 Cr | ₹12 Cr | ₹991 Cr | ₹69 Cr |
| Profit Before Tax | ₹1,671 Cr | ₹1,975 Cr | ₹169 Cr | ₹14,377 Cr | ₹875 Cr |
| Profit After Tax | ₹1,310 Cr | ₹1,453 Cr | ₹129 Cr | ₹10,561 Cr | ₹610 Cr |
| Consolidated Net Profit | ₹1,282 Cr | ₹1,433 Cr | ₹127 Cr | ₹10,304 Cr | ₹579 Cr |
| Earnings Per Share (Rs) | ₹47.75 | ₹32.00 | ₹35.78 | ₹31.59 | ₹25.72 |
| PAT Margin (%) | 18.06 | 14.38 | 18.00 | 20.00 | 17.31 |
| ROE(%) | 23.15 | 19.27 | 26.72 | 31.51 | 33.48 |
| ROCE(%) | 28.38 | 23.49 | 33.96 | 39.97 | 43.57 |
| Total Debt/Equity(x) | 0.02 | 0.02 | 0.14 | 0.05 | 0.04 |
Key Financials |
||
| Market Cap | : | ₹ 102,240.6 Cr |
| Revenue (TTM) | : | ₹ 11,018.0 Cr |
| Net Profit(TTM) | : | ₹ 2,124.9 Cr |
| EPS (TTM) | : | ₹ 53.0 |
| P/E (TTM) | : | 48.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| MANKIND PHARMA | -2.1% | -0.6% | 33.1% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.7% | -4.7% | 48.8% |
| CIPLA | -0.9% | -1.7% | 17.3% |
| DR REDDYS LABORATORIES | -1% | -8.9% | 6.5% |
| ZYDUS LIFESCIENCES | -1% | -4% | 48.4% |
| DIVIS LABORATORIES | 4.4% | 3.1% | 66% |
| TORRENT PHARMACEUTICALS | 2.2% | -5% | 49.1% |
| LUPIN | 2.8% | -2.9% | 70.8% |
| AUROBINDO PHARMA | -2% | -15.4% | 21.1% |
MANKIND PHARMA Revenues
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | 12.44 % |
| 5 Yr CAGR | 15.13 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹8,749 Cr | 12.44 | |
| Mar2023 | ₹7,782 Cr | 1,152.18 | |
| Mar2022 | ₹621 Cr | -98.94 | |
| Mar2021 | ₹58,719 Cr | 1,079.10 | |
| Mar2020 | ₹4,980 Cr | - | |
MANKIND PHARMA Operating Profit
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | -4.45 % |
| 5 Yr CAGR | 19.75 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,902 Cr | -4.45 | |
| Mar2023 | ₹1,991 Cr | 1,107.04 | |
| Mar2022 | ₹165 Cr | -98.86 | |
| Mar2021 | ₹14,447 Cr | 1,461.81 | |
| Mar2020 | ₹925 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -15.01 % |
| 5 Yr CAGR | 4.02 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 21.74% | -15.01 | |
| Mar2023 | 25.58% | -3.62 | |
| Mar2022 | 26.54% | 7.89 | |
| Mar2021 | 24.6% | 32.47 | |
| Mar2020 | 18.57% | - | |
MANKIND PHARMA Profit After Tax
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | -10.58 % |
| 5 Yr CAGR | 22.01 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,282 Cr | -10.58 | |
| Mar2023 | ₹1,433 Cr | 1,032.80 | |
| Mar2022 | ₹127 Cr | -98.77 | |
| Mar2021 | ₹10,304 Cr | 1,681.10 | |
| Mar2020 | ₹579 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 25.59 % |
| 5 Yr CAGR | 1.07 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 18.06 % | 25.59 | |
| Mar2023 | 14.38 % | -20.11 | |
| Mar2022 | 18 % | -10.00 | |
| Mar2021 | 20 % | 15.54 | |
| Mar2020 | 17.31 % | - | |
MANKIND PHARMA Earnings Per Share (EPS)
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | 49.22 % |
| 5 Yr CAGR | 16.73 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹48 | 49.22 | |
| Mar2023 | ₹32 | -10.56 | |
| Mar2022 | ₹36 | 13.26 | |
| Mar2021 | ₹32 | 22.82 | |
| Mar2020 | ₹26 | - | |
MANKIND PHARMA Return on Capital Employed (ROCE)
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | 20.82 % |
| 5 Yr CAGR | -10.16 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 28.38% | 20.82 | |
| Mar2023 | 23.49% | -30.83 | |
| Mar2022 | 33.96% | -15.04 | |
| Mar2021 | 39.97% | -8.26 | |
| Mar2020 | 43.57% | - | |
MANKIND PHARMA Share Price vs Sensex
| Current Share Price | : | ₹2,551.6 |
| Current MarketCap | : | ₹ 102,240.6 Cr |
| Updated EOD on | : | Nov 22,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | -2.1% |
-0.6% |
33.1% |
| SENSEX | -1.9% |
-5% |
17.5% |
MANKIND PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
| S&P BSE HEALTHCARE | -1.8% | -4.1% | 46.6% |
| S&P BSE 250 LARGEMIDCAP | -2.2% | -6.7% | 23.6% |
| S&P BSE 200 | -2.2% | -6.7% | 23.6% |
| S&P BSE LARGE MIDCAP | -2.2% | -6.8% | 23.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY FREE MIDCAP 100 | -1.6% | -7.3% | 31.4% |
| NIFTY MIDCAP150 | -1.9% | -7.2% | 30.8% |
| NIFTY PHARMA | -1.9% | -6.9% | 40.1% |
| NIFTY LARGE MIDCAP 250 | -2.1% | -7% | 26.7% |
| NIFTY MID SMALL400 | -2.1% | -7.6% | 30.6% |
You may also like the below Video Courses
FAQ about MANKIND PHARMA Financials
How the annual revenues of MANKIND PHARMA have changed ?
The Revenues of MANKIND PHARMA have increased by 12.44% YoY .
How the Earnings per Share (EPS) of MANKIND PHARMA have changed?
The Earnings Per Share (EPS) of MANKIND PHARMA has increased by 49.22 % YoY .
Check out Intrinsic Value of Peers of MANKIND PHARMA
Compare Stock Analytics of Peers of MANKIND PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
